Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir alafenamide fumarate + lamivudine + dolutegravir
- Development stage
- Preclinical
- Lead developer
- Shanghai Desano
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a fixed-dose combination (FDC) antiretroviral therapy being developed by Shanghai Desano Pharmaceutical for the treatment of HIV-1 infection. The regimen consists of three active pharmaceutical ingredients: dolutegravir (50mg), an integrase strand transfer inhibitor (INSTI); lamivudine (300mg), a nucleoside reverse transcriptase inhibitor (NRTI); and tenofovir alafenamide fumarate (25mg), a nucleotide reverse transcriptase inhibitor (NtRTI). By targeting both the reverse transcription and integration phases of the HIV life cycle, this combination provides a potent barrier to viral replication. The formulation is designed as a single oral tablet to simplify treatment regimens and is currently in the preclinical stage of development.
- Other names
- Tenofovir alafenamide fumarate/lamivudine/dolutegravir (25mg/300mg/50mg)
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseOCT2 (Organic cation transporter 2)SLC47A1 (Multidrug and toxin extrusion transporter 1)Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on tenofovir alafenamide fumarate + lamivudine + dolutegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir alafenamide fumarate + lamivudine + dolutegravir.